Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...

The company claims its Fertilo system can mature eggs outside the body using 80% fewer hormonal injections than typical methods.

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...

It’s not the first time Johnson’s pursuit of immortality has made the news. The 47-year-old allegedly spends about $2 million ...

Report with the AI impact on market trends - The global biotech market size is estimated to grow by USD 805.6 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

More than 10 million babies have been born through IVF, yet the process is still invasive and costly. Plus, why a venture ...